Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 23818211)

  • 1. The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.
    Hemmerle T; Neri D
    Int J Cancer; 2014 Jan; 134(2):467-77. PubMed ID: 23818211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.
    Pasche N; Wulhfard S; Pretto F; Carugati E; Neri D
    Clin Cancer Res; 2012 Aug; 18(15):4092-103. PubMed ID: 22693354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity.
    Hess C; Neri D
    Cancer Immunol Immunother; 2015 May; 64(5):635-44. PubMed ID: 25722088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis.
    Kaspar M; Trachsel E; Neri D
    Cancer Res; 2007 May; 67(10):4940-8. PubMed ID: 17510424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
    Hess C; Neri D
    Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.
    Frey K; Zivanovic A; Schwager K; Neri D
    Integr Biol (Camb); 2011 Apr; 3(4):468-78. PubMed ID: 21225052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.
    Villa A; Trachsel E; Kaspar M; Schliemann C; Sommavilla R; Rybak JN; Rösli C; Borsi L; Neri D
    Int J Cancer; 2008 Jun; 122(11):2405-13. PubMed ID: 18271006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8
    Puca E; Probst P; Stringhini M; Murer P; Pellegrini G; Cazzamalli S; Hutmacher C; Gouyou B; Wulhfard S; Matasci M; Villa A; Neri D
    Int J Cancer; 2020 May; 146(9):2518-2530. PubMed ID: 31374124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Targeted Delivery of Interleukin 4 Inhibits Development of Endometriotic Lesions in a Mouse Model.
    Quattrone F; Sanchez AM; Pannese M; Hemmerle T; Viganò P; Candiani M; Petraglia F; Neri D; Panina-Bordignon P
    Reprod Sci; 2015 Sep; 22(9):1143-52. PubMed ID: 25850899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-mediated delivery of interleukin 4 to the neo-vasculature reduces chronic skin inflammation.
    Hemmerle T; Zgraggen S; Matasci M; Halin C; Detmar M; Neri D
    J Dermatol Sci; 2014 Nov; 76(2):96-103. PubMed ID: 25190364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells.
    Adris S; Chuluyan E; Bravo A; Berenstein M; Klein S; Jasnis M; Carbone C; Chernajovsky Y; Podhajcer OL
    Cancer Res; 2000 Dec; 60(23):6696-703. PubMed ID: 11118055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.
    De Luca R; Neri D
    Cancer Immunol Immunother; 2018 Sep; 67(9):1381-1391. PubMed ID: 29971465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dose-dependent tumor targeting of antibody-IFNγ fusion proteins reveals an unexpected receptor-trapping mechanism in vivo.
    Hemmerle T; Neri D
    Cancer Immunol Res; 2014 Jun; 2(6):559-67. PubMed ID: 24795141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
    Pretto F; Elia G; Castioni N; Neri D
    Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis.
    Hemmerle T; Doll F; Neri D
    Proc Natl Acad Sci U S A; 2014 Aug; 111(33):12008-12. PubMed ID: 25092334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7.
    Pasche N; Woytschak J; Wulhfard S; Villa A; Frey K; Neri D
    J Biotechnol; 2011 Jun; 154(1):84-92. PubMed ID: 21527292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma.
    Frey K; Schliemann C; Schwager K; Giavazzi R; Johannsen M; Neri D
    J Urol; 2010 Dec; 184(6):2540-8. PubMed ID: 21030045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia.
    Gutbrodt KL; Schliemann C; Giovannoni L; Frey K; Pabst T; Klapper W; Berdel WE; Neri D
    Sci Transl Med; 2013 Sep; 5(201):201ra118. PubMed ID: 24005158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF.
    Schwager K; Hemmerle T; Aebischer D; Neri D
    J Invest Dermatol; 2013 Mar; 133(3):751-758. PubMed ID: 23096716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.